vasculitides

living with vasculitis

game changers

The MIRRA trial: Mepolizumab (Nucala) or placebo for the treatment of EGPA/Churg-Strauss Syndrome

Wechsler et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N. Engl. J. Med. 2017 376(20):1921-1932. Disclosure:  I was a patient in this clinical trial from March 2015 to May 2016 and I am still taking mepolizumab to treat my EGPA. For more details and a full list of my disclosures, please see the […]

The MIRRA trial: Mepolizumab (Nucala) or placebo for the treatment of EGPA/Churg-Strauss Syndrome Read More »

GiACTA-trial-tocilizumab-actemra-for-giant-cell-arteritis-gca

The GiACTA trial: Tocilizumab in Giant Cell Arteritis

Stone et al. Trial of Tocilizumab in Giant-Cell Arteritis. N. Engl. J. Med. 2017 377(4):317-328. NEJM Quick Take:  Click on the following link from the New England Journal of Medicine to view a 2 minute video summarizing the study results: video. Game changer:  Why is this study important? Tocilizumab is the first treatment, other than corticosteroids, shown

The GiACTA trial: Tocilizumab in Giant Cell Arteritis Read More »

Scroll to Top